Inke to triple capacity for inhalation API manufacturing

20-Apr-2022 - Last updated on 20-Apr-2022 at 14:03 GMT

(Photo: Inke)

The maker of active pharmaceutical ingredients for inhaled treatments is investing €9m ($9.8m USD) to expand its manufacturing plant in Barcelona, Spain.

Inke, a manufacturer of inhalation active pharmaceutical ingredients (APIs) owned by Neuraxpharm Group, has announced plans to invest €9m (approximately $9.8m USD) to increase its capacity to produce APIs. According to the company, the investment will enable the tripling of the production capacity of chemical synthesis and the micronization of inhalation APIs at its manufacturing plant in Castellbisbal, Barcelona, by 2024 (with about 80% of the funds deployed by the end of 2022.

Expansion of the multipurpose plant reportedly will enable the company to better meet the increasing global demand for inhalation APIs. Air pollution and an aging global population are among the factors leading to an increase in respiratory ailments.

Inke has more than 20 years of experience providing micronization and particle engineering expertise, According to the company, it has established preferential relationships with the main inhalation players worldwide, with unique access to the highly demanding Japanese market.

Jörg Thomas Dierks, CEO of Neuraxpharm, said, "Inke is a key supplier to major generic and branded companies in over 40 countries due to its very strong and entrenched competitive position. The segment of micronized inhalation APIs is highly attractive and poised for future growth, and I am convinced that this investment contributes significantly to extending our leading position in this market."

Miquel Bachs, Inke’s general manager, commented, "We expect the increased global demand for respiratory APIs will allow us to grow our business considerably and to further strengthen our market position as a leading global API supplier specialized in inhalation therapies. I am proud that with this investment, Inke's production site in the province of Barcelona is made future-proof."

The company’s operational team includes manufacturing, R&D, regulatory, commercial, administrative, and other support functions Following the appointment of Bachs as general manager, Inke has had a new management team driving the commercial strategy, with a focus on third-party sales.

Inke developed its first respiratory product in 1998. The site currently produces 34 APIs by chemical synthesis processes and reportedly ranks among the top European respiratory API pharmaceutical manufacturing companies with the most patent filings in the last ten years. certifications.